Molecular mechanism of EAG1 channel inhibition by imipramine binding to the PAS domain

• Published in: The Journal of biological chemistry 2023-12, Vol.299 (12), p.105391-105391, Article 105391
• Main Authors: Wang, Ze-Jun, Ghorbani, Mahdi, Chen, Xi, Tiwari, Purushottam B., Klauda, Jeffery B., Brelidze, Tinatin I.
• Format: Article
• Language: English
• Subjects: EAG; gating; inhibition mechanism; inhibitor; KCNH1; Kv10.1 channels; ligand-binding protein; potassium channel
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/j.jbc.2023.105391

Ether-a-go-go (EAG) channels are key regulators of neuronal excitability and tumorigenesis. EAG channels contain an N-terminal Per-Arnt-Sim (PAS) domain that can regulate currents from EAG channels by binding small molecules. The molecular mechanism of this regulation is not clear. Using surface plasmon resonance and electrophysiology we show that a small molecule ligand imipramine can bind to the PAS domain of EAG1 channels and inhibit EAG1 currents via this binding. We further used a combination of molecular dynamics (MD) simulations, electrophysiology, and mutagenesis to investigate the molecular mechanism of EAG1 current inhibition by imipramine binding to the PAS domain. We found that Tyr71, located at the entrance to the PAS domain cavity, serves as a “gatekeeper” limiting access of imipramine to the cavity. MD simulations indicate that the hydrophobic electrostatic profile of the cavity facilitates imipramine binding and in silico mutations of hydrophobic cavity-lining residues to negatively charged glutamates decreased imipramine binding. Probing the PAS domain cavity-lining residues with site-directed mutagenesis, guided by MD simulations, identified D39 and R84 as residues essential for the EAG1 channel inhibition by imipramine binding to the PAS domain. Taken together, our study identified specific residues in the PAS domain that could increase or decrease EAG1 current inhibition by imipramine binding to the PAS domain. These findings should further the understanding of molecular mechanisms of EAG1 channel regulation by ligands and facilitate the development of therapeutic agents targeting these channels.